Human Soluble Receptor for Advanced Glycation End Products (sRAGE) for Treating Vascular Disease, Injury, or Inflammation


The receptor for advanced glycation end products (RAGE) is a protein implicated in the development of vascular hyperplasia and in atherogenesis. RAGE is a cell surface protein that triggers signaling pathways leading to inflammation and RAGE-stimulated inflammation can contribute to adverse inflammatory conditions, such as atherosclerosis and arterial restenosis (a serious pathological complication that can follow surgical cardiovascular interventions like angioplasty).

Researchers at the National Institute on Aging (NIA) have developed methods to produce a soluble receptor for advanced glycation end products (sRAGE) in mammalian cells and the use of sRAGE for the treatment of vascular diseases and disorders, given that sRAGE has mammalian post-translational modifications. Further, sRAGE has been used to treat arterial restenosis and atherosclerosis in animal models. sRAGE, is used as a therapeutic agent that is believed to act as a decoy to diminish RAGE-dependent signaling, thereby attenuating inflammation and pathogenic consequences. sRAGE also has been associated with anti-mitotic effects.

Potential Commercial Applications: Competitive Advantages:
  • Prevention of vascular inflammation
  • Treatment for any disease, disorder, condition, injury, or inflammation that primarily affects the blood vessels
  • Treatment of vascular diseases such as atherosclerosis, restenosis, angina, myocardial ischemia, or any condition associated with cardiovascular inflammation
  • Treatment of Alzheimer's disease
 
  • Greater than 1000-fold increased potency over sRAGE produced in insect cells
  • Treatment methods claimed by the patent span a wide array of indications
  • Readily scalable production of materials utilized in treatment regimens
  • Routes of administration of sRAGE include intravenous, intraarterial, intramuscular, intraperitoneal, intrathecal, epidural, topical, percutaneous, subcutaneous, transmucosal, intranasal, and oral


Development Stage:
  • Early-stage
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Inventors:

Li Lin (NIA)  ➽ more inventions...

Edward Lakatta (NIA)  ➽ more inventions...

Sungha Park (NIA)  ➽ more inventions...

Hyun-Jin Tae (NIA)  ➽ more inventions...

Wen Wei (NIA)  ➽ more inventions...

Natalia Petrashevskaya (NIA)  ➽ more inventions...

Rui-ping Xiao (NIA)  ➽ more inventions...

Mark Talan (NIA)  ➽ more inventions...

Ismayil Ahmet (NIA)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 9,175,062 issued 2015-11-03
PCT Application No. PCT/US2013/020103
US Application No. 61/582,574

Collaboration Opportunity:

The National Institute on Aging, Laboratory of Cardiovascular Science, seeks licensing partners and statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize sRAGE.


Licensing Contact:
Richard Girards, J.D., M.B.A.
Email: richard.girards@nih.gov
Phone: 240-276-6825

OTT Reference No: E-165-2011/0
Updated: Jun 29, 2017